🔎 Trials Near Me

Home › Scleroderma › Pennsylvania › Philadelphia

Scleroderma clinical trials in Philadelphia, PA

6 studies for Scleroderma are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

RecruitingPhase 2
  • Perelman Center for Advanced Medicine, Philadelphia
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06655155

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

RecruitingPhase 3
  • University of Pennsylvania, Philadelphia
  • Thomas Jefferson University, Philadelphia
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07497087

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

RecruitingPhase 2/3
  • GSK Investigational Site, Philadelphia
  • GSK Investigational Site, Philadelphia
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717

Platform Clinical Study for Conquering Scleroderma

RecruitingPhase 2
  • University of Pennsylvania, Philadelphia
  • Thomas Jefferson University Hospital, Philadelphia
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

RecruitingPhase 1
  • Jefferson Einstein Hospital Philadelphia, Philadelphia
Ages 12 to 70 · All sexes · Updated May 22, 2026 · NCT06308978

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

RecruitingPhase 2
  • Children's Hospital of Philadelphia, Philadelphia
Ages 8 to 25 · All sexes · Updated Oct 14, 2025 · NCT05029336

About Scleroderma

Scleroderma is an autoimmune disease that causes inflammation and thickening in the skin and other areas of the body. The exact cause of scleroderma is unknown.

More about Scleroderma on MedlinePlus

Scleroderma trials in other cities

Other studies in Philadelphia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.